Trials / Recruiting
RecruitingNCT06609759
Postoperative Adjuvant Therapy for Stage II-III Gastric Cancer
Efficacy and Safety of Postoperative Adjuvant Therapy for Stage II-III Gastric Cancer: a Prospective, Observational Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 197 (estimated)
- Sponsor
- Qilu Hospital of Shandong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
For patients with stage II-III gastric cancer after radical D2 resection and R0 resection, postoperative adjuvant therapy guided by ctDNA-MRD (MRD-GATE external cohort) was not inferior to the standard chemotherapy regimen (this cohort).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Standard chemotherapy regimen | In terms of postoperative adjuvant treatment, treatment is based on the guideline standard treatment plan, which can be adjusted according to the doctor's experience. |
Timeline
- Start date
- 2024-01-01
- Primary completion
- 2028-01-01
- Completion
- 2029-01-01
- First posted
- 2024-09-24
- Last updated
- 2024-09-24
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06609759. Inclusion in this directory is not an endorsement.